Tag: adverse event monitoring

Severity Grading of Adverse Events Using CTCAE Guidelines

Posted on digi By digi

Severity Grading of Adverse Events Using CTCAE Guidelines Applying CTCAE Guidelines for Severity Grading of Adverse Events Introduction: Why Severity Grading Matters Severity grading is one of the most critical aspects of adverse event (AE) assessment in clinical trials. Regulators including the FDA, EMA, and MHRA require investigators to classify the intensity of each AE…

Read More “Severity Grading of Adverse Events Using CTCAE Guidelines” »

Adverse Event Reporting and Management, Causality and Severity Assessments

Source Documentation for Adverse Events in Clinical Trials

Posted on digi By digi

Source Documentation for Adverse Events in Clinical Trials How to Properly Document Adverse Events in Source Records During Clinical Trials In clinical trials, every reported Adverse Event (AE) must be backed by accurate and verifiable source documentation. Proper AE documentation ensures the integrity of safety data, facilitates sponsor and regulatory review, and supports Good Clinical…

Read More “Source Documentation for Adverse Events in Clinical Trials” »

Adverse Event Reporting, Safety Reporting and Pharmacovigilance

Phase I Clinical Trials: Safety, Dosage, and Early Human Studies

Posted on digi By digi

Phase I Clinical Trials: Safety, Dosage, and Early Human Studies Understanding Phase I Clinical Trials: Safety, Dosage, and First-in-Human Studies Phase I clinical trials are the critical first step in testing new treatments in humans. Focused primarily on safety and dosage, these studies provide the foundation for all subsequent clinical development. Understanding Phase I design…

Read More “Phase I Clinical Trials: Safety, Dosage, and Early Human Studies” »

Clinical Trial Phases, Phase 1 (Safety and Dosage)